Last $46.09 USD
Change Today -0.53 / -1.14%
Volume 5.6M
ZTS On Other Exchanges
Symbol
Exchange
New York
Berlin
As of 8:04 PM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

zoetis inc (ZTS) Snapshot

Open
$46.54
Previous Close
$46.62
Day High
$46.88
Day Low
$46.04
52 Week High
02/12/15 - $47.40
52 Week Low
04/15/14 - $28.14
Market Cap
23.1B
Average Volume 10 Days
3.8M
EPS TTM
$1.41
Shares Outstanding
500.8M
EX-Date
04/7/15
P/E TM
32.7x
Dividend
$0.33
Dividend Yield
0.65%
Current Stock Chart for ZOETIS INC (ZTS)

zoetis inc (ZTS) Details

Zoetis Inc. is engaged in the discovery, development, manufacture, and commercialization of animal health medicines and vaccines for livestock and companion animals worldwide. It operates through four segments: United States, Europe/Africa/Middle East, Canada/Latin America, and Asia/Pacific. The company offers anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; vaccines that are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; and parasiticides that prevent or eliminate external and internal parasites, such as fleas, ticks, and worms. It also provides medicated feed additives that offer medicines to livestock; veterinarian solutions for anesthesia and treating pain and serious illnesses, such as diabetes; and other pharmaceutical products, including pain and sedation, oncology, antiemetic, allergy, and dermatology products, as well as reproductive products. The company markets its products to veterinarians and livestock producers through its sales representatives, and technical and veterinary operations specialists. Zoetis Inc. was founded in 1952 and is headquartered in Florham Park, New Jersey.

10,000 Employees
Last Reported Date: 02/11/15
Founded in 1952

zoetis inc (ZTS) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $825.0K
Group President and Executive Vice President
Total Annual Compensation: $605.0K
Executive Vice President and President of U.S...
Total Annual Compensation: $400.0K
President of Research & Development and Execu...
Total Annual Compensation: $400.0K
Compensation as of Fiscal Year 2013.

zoetis inc (ZTS) Key Developments

Zoetis Inc. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Full year Ended December 31, 2014; Revises Earnings Guidance for 2015

Zoetis Inc. announced unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported revenue of $1,320 million against $1,254 million a year ago. Income before provision for taxes on income was $155 million against $126 million a year ago. Net income attributable to the company was $126 million against $105 million a year ago. Diluted earnings per share were $0.25 against $0.21 a year ago. Non-GAAP income before provision for taxes on income was $249 million against $252 million a year ago. Non-GAAP net income attributable to the company was $203 million against $180 million a year ago. Non-GAAP diluted earnings per common share attributable to the company were $0.40 against $0.36 a year ago. For the year, the company reported revenue of $4,785 million against $4,561 million a year ago. Income before provision for taxes on income was $820 million against $690 million a year ago. Net income attributable to the company was $583 million against $504 million a year ago. Diluted earnings per share were $1.16 against $1.01 a year ago. Non-GAAP income before provision for taxes on income was $1,084 million against $1,000 million a year ago. Non-GAAP net income attributable to the company was $790 million against $709 million a year ago. Non-GAAP diluted earnings per common share attributable to the company were $1.57 against $1.42 a year ago. For 2015, the company expects revenue to be in the range of $4,800 million to $4,900 million against $4,850 million to $4,950 million as previously expected. The company expects operational growth to be in the range of 6.5% to 8.5%. Effective tax rate on adjusted income approximately 29%. The company expects adjusted diluted EPS to be in the range of $1.61 to $1.68 and adjusted net income to be in the range of $810 million to $845 million. The company expects reported diluted EPS to be in the range of $1.32 to $1.39 against $1.36 to $1.43 as previously expected. The company expects reported net income attributable to the company to be in the range of $665 million to $700 million. Adjusted interest expense and other (income)/deductions of approximately $110 million.

Zoetis Inc. Appoints William Doyle as Director, to Serve as Member of the Corporate Governance Committee of the Board

On February 3, 2015, the Board of Directors of Zoetis Inc. appointed Mr. William Doyle to serve as a director of the company with a term expiring at the 2016 Annual Meeting, with such appointment to be effective immediately. The Board also appointed Mr. Doyle to serve as a member of the Corporate Governance Committee of the Board. In connection with the appointment of Mr. Doyle, the size of the Board of Directors of the company was increased from nine to ten members.

Investors Reportedly Eyes Stake In Zoetis

Bill Ackman, the billionaire hedge fund activist, has parachuted one of his representatives on to the Board of Zoetis Inc. (NYSE:ZTS), he is trying to shake up or sell. People familiar with his thinking say he will push for a sale of Zoetis if it does not start making progress by the middle of the year. Bayer AG (DB:BAYN) and Novartis AG (SWX:NOVN) both expressed interest in buying Zoetis before it was carved out of Pfizer, but the rules governing spin-offs made it difficult for them to acquire it during the two years after it became fully independent. That two-year period ends in June.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ZTS:US $46.09 USD -0.53

ZTS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abaxis Inc $60.92 USD -0.54
IDEXX Laboratories Inc $156.83 USD -1.20
Phibro Animal Health Corp $36.27 USD -0.12
Valneva SE €4.75 EUR -0.04
Virbac SA €239.35 EUR -1.20
View Industry Companies
 

Industry Analysis

ZTS

Industry Average

Valuation ZTS Industry Range
Price/Earnings 40.1x
Price/Sales 4.9x
Price/Book 17.1x
Price/Cash Flow 36.3x
TEV/Sales 4.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ZOETIS INC, please visit www.zoetis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.